Protalix Biotherapeutics Inc (NYSE American:PLX)

0.28
Delayed Data
As of 8:00pm ET
 +0.007 / +2.56%
Today’s Change
0.17
Today|||52-Week Range
0.60
-9.97%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$45.2M

Company Description

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Contact Information

Protalix Biotherapeutics, Inc.
2 Snunit Street
Carmiel Hazafon 21614
P:(724) 902-8100
Investor Relations:

Employees

Shareholders

Mutual fund holders5.22%
Other institutional4.98%
Individual stakeholders18.46%

Top Executives

There are no executives to display.